To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

September 26, 2018

Today's Rundown

Featured Story

Alexion snaps up another biotech, paying $1.2B for Syntimmune

Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for rare disease specialist Syntimmune.

Top Stories

Aldeyra plans reproxalap phase 3 after wrapping up dry eye disease trial

Aldeyra Therapeutics’ reproxalap has improved ocular dryness and discomfort in patients with dry eye disease in a phase 2b clinical trial. The results tee Aldeyra up to move the aldehyde-binding small molecule into phase 3 next year.

Lyra bags $29.5M to push chronic sinusitis drug into phase 2

Lyra Therapeutics' $29.5 million series B will move its lead program, a treatment for chronic rhinosinusitis, into phase 2. The asset, LYR-210, is based on its transmucosal drug delivery platform.

Roche-backed Minoryx raises €21M to expand CNS R&D

Minoryx has raised €21.3 million in series B funding. The round sets Minoryx up to expand clinical development of a neurodegenerative disease drug that has attracted the interest of investors including Roche Venture Fund.

Curis moves up COO as CEO Fattaey leaves company

Curis has promoted its chief operating officer James Dentzer to the lead the company, effective immediately, following the departure of CEO Ali Fattaey.

Blueprint’s Tagrisso combination shows early promise in NSCLC

Blueprint Medicines presented data from two patients showing that a combination of its RET inhibitor BLU-667 and AstraZeneca’s tyrosine kinase inhibitor Tagrisso could potentially beat treatment resistance in patients with non-small cell lung cancer.

GlaxoSmithKline tuberculosis vaccine shows promise in phase 2b

GlaxoSmithKline and its nonprofit partner Aeras touted results for what could be a promising vaccine against tuberculosis, a leading cause of death worldwide.

Resources

[eBook] Healthcare and Life Sciences - Data Value Chain

Download our new eBook to learn how Healthcare and Life Sciences organizations are taking advantage of solutions from AWS and the AWS Partner Network to obtain value from critical data.

[POCKET GUIDE] 3 Steps To Supercharge Your Literature Search

Go from Search to Full-Text Scientific Papers in a Single Click!

[Infographic] Flexible. Scalable. Proactive.

Covance FSPx boasts one of the world’s largest dedicated FSP groups in the contract research organization space with ~4200 staff in 60+ countries.

[Case Study] FSP Insourcing – Relationship Growth Built on Results, Trust

Covance FSPx boasts one of the world’s largest dedicated FSP groups in the contract research organization space with ~4200 staff in 60+ countries.

[eBook] Digital Workflows: How to Focus Investment to Cut Costs and Drive Growth

Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin?

[Whitepaper] How to Re-Design your Regulatory Capabilities

A top 20 pharma and growing biotech re-engineer regulatory processes.

[Whitepaper] The Future of Pharmacovigilance: Leveraging Technology and Automation

Are automation, big data and artificial intelligence (AI) a key part of your company’s pharmacovigilance strategy? Read this whitepaper to know what they should be!

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

[Whitepaper] Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs

When developing a parenteral, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages.

[Whitepaper] Scale-Up and Technical Transfer for Lyophilized Products

Baxter BioPharma Solutions’ whitepaper offers a method to address the challenges of tech transfer for lyophilized products from lab-scale to commercial-scale.

[Whitepaper] Addressing the Special Commercial Challenges in Rare Diseases

A whitepaper outlining the key commercial challenges facing rare disease products, and how biopharmaceutical companies can overcome them.

[Webinar] Enabling precision medicine with Tableau and AWS

Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children.

[Webinar] Build a holistic data management strategy for Life Sciences

Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS.

[Webinar] Safeguard your Life Sciences data with Druva and AWS

Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data.

[eLearning] BIOAVAILABILITY 101

Develop a basic understanding of principles and concepts of bioavailability of oral drugs.

Events

.